Nab-paclitaxel in patients with metastatic melanoma

References

• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol: Official J Am Soc Clin Oncol. 2009;27:6199.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer. 2013;119:586.
   PubMed Web of Science ®Google Scholar
• Spitler LE, Boasberg P, O’Day S, et al. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Am J Clin Oncol. 2015;38:61.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr. 1993;15:185.
   PubMedGoogle Scholar
• Hodi FS, Soiffer RJ, Clark J, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283.
   PubMed Web of Science ®Google Scholar
• Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531.
   PubMed Web of Science ®Google Scholar
• Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375.
   PubMed Web of Science ®Google Scholar
• Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980;77:1561.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454.
   PubMed Web of Science ®Google Scholar
• Briggs J, Chamboredon S, Castellazzi M, et al. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene. 2002;21:7077.
   PubMed Web of Science ®Google Scholar
• Gilles C, Bassuk JA, Pulyaeva H, et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998;58:5529.
   PubMed Web of Science ®Google Scholar
• Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res. 2005;65:7370.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res. 2003;63:5376.
   PubMed Web of Science ®Google Scholar
• Ledda F, Bravo AI, Adris S, et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Investigative Dermatol. 1997;108:210.
   PubMed Web of Science ®Google Scholar
• Ledda MF, Adris S, Bravo AI, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med. 1997;3:171.
   PubMed Web of Science ®Google Scholar
• Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell. 2003;14:3977.
   PubMed Web of Science ®Google Scholar
• Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res: Official J Am Association Cancer Res. 2000;6:1140.
   PubMed Web of Science ®Google Scholar
• Thomas S, Waterman P, Chen S, et al. Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer. J Nanomed Nanotechnol. 2011;2:112.
   Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids. 2005;72:267.
   PubMed Web of Science ®Google Scholar
• Yeh TK, Lu Z, Wientjes MG, et al. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res. 2005;22:867.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, et al. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol. 2009;2:59.
   PubMed Web of Science ®Google Scholar
• Markovic S, Suman V, Trieu VN, et al. Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E. ASCO Meet Abstr. 2010;28:8578.
   Google Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res: Official J Am Association Cancer Res. 2002;8:1038.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol. 2007;60:759.
   PubMed Web of Science ®Google Scholar
• Hersh EM, O’Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116:155.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol: Official J Am Soc Clin Oncol. 2006;24:4738.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol: Official J Am Soc Clin Oncol. 2000;18:158.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer. 2011;117:1704.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol: Official J Am Soc Clin Oncol. 2008;26:5326.
   PubMed Web of Science ®Google Scholar
• Stein WD, Yang J, Bates SE, et al. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008;13:1055.
   PubMed Web of Science ®Google Scholar
• Hersh E, Del Vecchio M, Brown MP, et al. Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma. ASCO Meet Abstr. 2014;32:9045.
   Google Scholar
• Hersh E, Del Vecchio M, Brown MP, et al. A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status. ASCO Meet Abstr. 2013;31:9030.
   Google Scholar
• Javeed A, Ashraf M, Riaz A, et al. Paclitaxel and immune system. Eur J Pharmaceutical Sci: Official J Eur Fed Pharm Sci. 2009;38:283.
   PubMed Web of Science ®Google Scholar
• Alrwas A, Papadopoulos NE, Cain S, et al. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Res. 2014;24:342.
   PubMed Web of Science ®Google Scholar
• Liao JB, Swensen RE, Reichow J, et al. Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: clinical and immune responses. ASCO Meet Abstr. 2015;33:5580.
   Google Scholar